DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on XRAY. Barclays reiterated a “hold” rating and set a $39.00 target price on shares of DENTSPLY SIRONA in a report on Sunday, January 6th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Sunday, January 6th. Barrington Research reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Friday, November 9th. Goldman Sachs Group upgraded DENTSPLY SIRONA from a “sell” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Friday, October 19th. Finally, ValuEngine upgraded DENTSPLY SIRONA from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 24th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $51.33.

XRAY opened at $40.71 on Friday. DENTSPLY SIRONA has a 52-week low of $33.93 and a 52-week high of $65.90. The stock has a market cap of $8.82 billion, a P/E ratio of 15.30, a P/E/G ratio of 2.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, November 8th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.08). DENTSPLY SIRONA had a positive return on equity of 8.68% and a negative net margin of 41.97%. The company had revenue of $928.40 million for the quarter, compared to the consensus estimate of $951.58 million. During the same quarter in the previous year, the company posted $0.70 EPS. The business’s revenue was down 8.0% on a year-over-year basis. Equities research analysts predict that DENTSPLY SIRONA will post 1.97 EPS for the current year.

In other news, insider Markus Boehringer sold 7,373 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $37.86, for a total value of $279,141.78. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.93% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Veritas Asset Management LLP boosted its stake in shares of DENTSPLY SIRONA by 18.2% in the third quarter. Veritas Asset Management LLP now owns 11,928,003 shares of the medical instruments supplier’s stock valued at $450,163,000 after buying an additional 1,835,402 shares during the period. Mackenzie Financial Corp boosted its stake in shares of DENTSPLY SIRONA by 47.0% in the third quarter. Mackenzie Financial Corp now owns 8,599,922 shares of the medical instruments supplier’s stock valued at $324,561,000 after buying an additional 2,749,915 shares during the period. First Eagle Investment Management LLC boosted its stake in shares of DENTSPLY SIRONA by 315.6% in the third quarter. First Eagle Investment Management LLC now owns 6,155,959 shares of the medical instruments supplier’s stock valued at $232,326,000 after buying an additional 4,674,605 shares during the period. Morgan Stanley boosted its stake in shares of DENTSPLY SIRONA by 1,233.9% in the third quarter. Morgan Stanley now owns 5,242,702 shares of the medical instruments supplier’s stock valued at $197,860,000 after buying an additional 4,849,652 shares during the period. Finally, Atlanta Capital Management Co. L L C boosted its stake in shares of DENTSPLY SIRONA by 0.4% in the third quarter. Atlanta Capital Management Co. L L C now owns 4,754,247 shares of the medical instruments supplier’s stock valued at $179,425,000 after buying an additional 18,007 shares during the period. 96.21% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Further Reading: How To Calculate Debt-to-Equity Ratio

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.